HC Wainwright Lowers Earnings Estimates for Brainsway

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Brainsway in a research report issued to clients and investors on Monday, August 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.38 per share for the year, down from their prior forecast of $0.42. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.34 per share.

A number of other research firms have also recently commented on BWAY. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. LADENBURG THALM/SH SH raised their target price on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research note on Thursday, August 13th. BTIG Research boosted their price target on shares of Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings lowered Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 19th. Finally, Zacks Research downgraded Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Brainsway presently has an average rating of “Moderate Buy” and an average target price of $18.20.

Brainsway Trading Down 1.7%

Shares of NASDAQ:BWAY opened at $14.27 on Wednesday. Brainsway has a 12-month low of $7.14 and a 12-month high of $17.40. The company has a market cap of $573.50 million, a PE ratio of 32.43 and a beta of 1.24. The stock has a 50 day moving average of $15.21 and a 200 day moving average of $14.65.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The company had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.54 million.

Hedge Funds Weigh In On Brainsway

Several hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its position in Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares during the period. Raymond James Financial Inc. bought a new position in shares of Brainsway during the second quarter valued at approximately $85,000. UBS Group AG grew its stake in shares of Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after buying an additional 60,877 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Brainsway in the third quarter worth approximately $107,000. 30.11% of the stock is currently owned by institutional investors.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.